Clinical Diagnostics And Research


The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer's Disease diagnostics


("MYND" or the

"Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC.

("MYND Diagnostics ") has commenced clinical research on a testing procedure for diagnosing and monitoring Alzheimer's Disease ("

AD ") utilizing the Company's proprietary anti-inflammatory peptide ("

MAP ") biomarker.

"Our research team has begun to research and explore the potential application of our proprietary MAP biomarker for use in the identification of Alzheimers disease", stated Dr. Lyle Oberg, CEO of MYND. "The ability to make an early, accurate, dependable diagnosis in Alzheimer's Disease patients thereby allowing for earlier intervention is a huge step forward in the fight against this terrible disease. We are extremely excited that the MAP biomarker has the potential to bridge that gap. The Company's ultimate goal specific to diagnostics is to provide a cost-effective, easy to use diagnostic test kit that can be administered from anywhere with a dried blood spot. Helping families and health care practitioners with an effective tool for early diagnosis, monitoring and treatment for the millions impacted by this disease will be a significant innovation in central nervous system medicine".

MYND Diagnostics will be initiating a clinical validation of the MAP biomarker in AD by collecting known blood samples of AD and quantifying the presence of MAP against control samples. This validation is planned to start in first quarter 2022.  Pending those results, the Company anticipates that a submission for FDA approval could take place as early as second half 2022 to prepare for commercialization and making the MAP Biomarker available to the public through healthcare practitioners. The Company's goal is to develop diagnostic test to monitor and potentially diagnose inflammatory diseases of the central nervous system such as Alzheimer's Disease. The Company's diagnostic test is intended to give health care providers an objective monitoring tool to improve patient outcomes by providing more tailored and efficacious treatments.

Approximately 44 million people worldwide live with AD or a related form of dementia.1  It is the sixth-leading cause of death in the U.S., killing more people than breast cancer and prostate cancer combined.2 Only approximately one in four people with the disease get diagnosed.3 Further, the Alzheimer's disease diagnostics and therapeutics market was valued at USD 6.6 billion in 2020, and it is expected to reach approximately USD 9 billion in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026.4





4 therapeutics?utm_source=BW&utm_medium=PressRelease&utm_code=stxjrv&utm_campaign=1533504+-+Alzheimer%27s+Disease+Diagnostics+and+Therapeutics+Market+-+Global+Growth%2c+Trends%2c+COVID-19+Impact%2c+and+Forecasts+2021-2026%3a+Focus+on+Cholinesterase+Inhibitors+%26+NMDA+Receptor+Antagonists&utm_exec=chdo54prd

Source :

MYND Diagnostics Commences Clinical Research on Alzheimer's Disease
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
Clinical Diagnostic Market Share 2022 Report Contains Manufacturing Cost Structure Analysis, Growth Opportunities and Restraints to 2026
Companion Animal Diagnostics Market To Reach A Value Of ~US$ 5 Bn By 2027: Transparency Market Research
Trending Report on Medical Device and Diagnostics Contract Market, 2021-2026
Novarad and PenRad partner to provide further diagnostic tracking functionality to healthcare providers
Global Clinical Laboratory Diagnostics Services Market 2021 Report Explores Key Regions, Company Profile, Opportunity and Challenge to 2027
Philips launches new AI-enabled MR portfolio of smart diagnostic systems, optimized workflow solutions and integrated clinical solutions at RSNA 2021
[LIMITED STOCK!] Related eBay Products